GETTING TO ACCESS : What price is right? Pharmaceutical pricing for Canadians

download GETTING TO ACCESS : What price is right? Pharmaceutical pricing for Canadians

of 9

  • date post

    12-Apr-2017
  • Category

    Healthcare

  • view

    11
  • download

    0

Embed Size (px)

Transcript of GETTING TO ACCESS : What price is right? Pharmaceutical pricing for Canadians

  • What price is right? Pharmaceutical pricing for Canadians.

    Carole Watson, Director, Strategic Pricing, Janssen Inc.

    GETTING TO ACCESS Innovative approaches to innovative medicines Canadian Organization for Rare Disorders March 29, 2017. Vancouver

  • GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

    Artwork by Sebastian Ferreira Janssen is proud to feature artwork created by people affected

    by the illnesses and diseases we are committed to treating and preventing.

  • GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

    Then Now Types of medicines: Large populations + lower cost / patient Small populations + higher cost / patient

    Local pricing decisions Globalized pricing frameworks

    List Prices HTA, ICERs pCPA: Confidential rebates Private Payer agreements

    Wide array of science Targeted science

    Innovation threshold lower Higher innovation level required for success

    R&D investment large scale centres R&D investment across the Life Sciences Ecosystem

    Randomized Controlled Trials RCTs + Real World Evidence

    Stronger economies Prolonged economic slowdown

    Younger populations Older populations

    Treated in hospitals Treated in the community

  • Canadian reimbursement environment is still rapidly evolving

    Health Canada Patented Medicine Prices Review Board

    HTA (CDR, INESSS, pCODR)

    Pan Canadian Pharmaceutical Alliance (pCPA)

    Private Insurer Assessments

    Provincial Payer Listings (PLAs)

    Drugwatch type programs

    Price and value hurdles between innovation and patients in Canada

    3/29/17

    GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

  • 3/29/17 GETTING TO ACCESS

    Innovative approaches to innovative medicines Canadian Organization for Rare Disorders

    March 29, 2017. Vancouver .

  • Patients are always at the center

    Broad understanding of value to patients, healthcare system, society

    Access for patients today

    Incentive for investment in biomedical innovation to transform the lives of patients tomorrow

    Medicines are priced to ensure patient access today and tomorrow

    3/29/17

    GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

  • Source:CIHI(NHEX),PMPRBAnnualReport2015,StatisticsCanada.MethodologyinspiredbyBrettSkinner.SpendingonPatentedMedicinesinCanada.CHPI,2016.CalculationsbyInnovativeMedicinesCanada,September2016..*CAGR2005-2014

    15%

    25%

    60%

    0

    1000

    2000

    3000

    4000

    5000

    6000

    +4.1% CAGR*

    Non-Drug Costs: +8.4% CAGR*

    PatentedDrugs:+0.8%CAGR*

    Healthcare Sustainability: Innovative Drugs and Beyond

    $, Per Capita

    20%

    32%

    48%

    Non-drug costs

    Non-Patented drugs

    Patented drugs

    GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

    Non-PatentedDrugs:+7.6%CAGR*

    Total Drug Costs:

    All Other Health, Excluding Drugs

  • Dr. Paul Janssen

    There are still many diseases for which there is no cure, and effective medicines must be found.

    Although we have contributed to the solutions for some of these problems, we will continue our research efforts, because so much more needs to be done.

    3/29/17

    GETTING TO ACCESS Innovative approaches to innovative medicines

    Canadian Organization for Rare Disorders March 29, 2017. Vancouver

    .

  • What price is right? Pharmaceutical pricing for Canadians.

    Carole Watson, Director, Strategic Pricing, Janssen Inc.

    GETTING TO ACCESS Innovative approaches to innovative medicines Canadian Organization for Rare Disorders March 29, 2017. Vancouver